These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29099349)

  • 21. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
    N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CFTR protein repair therapy in cystic fibrosis.
    Quintana-Gallego E; Delgado-Pecellín I; Calero Acuña C
    Arch Bronconeumol; 2014 Apr; 50(4):146-50. PubMed ID: 24095197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing.
    Hoppe JE; Zemanick ET; Martiniano SL
    Am J Respir Crit Care Med; 2022 Dec; 206(11):1308-1310. PubMed ID: 35947636
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transformative therapies for rare CFTR missense alleles.
    Oliver KE; Han ST; Sorscher EJ; Cutting GR
    Curr Opin Pharmacol; 2017 Jun; 34():76-82. PubMed ID: 29032041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Rehman A; Baloch NU; Janahi IA
    N Engl J Med; 2015 Oct; 373(18):1783. PubMed ID: 26510035
    [No Abstract]   [Full Text] [Related]  

  • 28. ELX/TEZ/IVA use in cystic fibrosis liver disease: Is the perspective of improved lung function worth the risk?
    Gardiner A; Volovets A; Haber P; Jo H; Visser S; Yozghatlian V; Taylor N; Nolan S; Dentice R; Malouf M; Marinelli T; Sivam D
    J Cyst Fibros; 2022 Sep; 21(5):881-884. PubMed ID: 35760705
    [No Abstract]   [Full Text] [Related]  

  • 29. Unlocking the power of pharmacy services and accelerating access to medications: An update to the impact of pharmacy services on cystic fibrosis transmembrane conductance regulator modulator prescribing at a pediatric cystic fibrosis center.
    Wright BA; Knockel LM
    Pediatr Pulmonol; 2024 Feb; 59(2):526-527. PubMed ID: 38018663
    [No Abstract]   [Full Text] [Related]  

  • 30. Ivacaftor for patients with cystic fibrosis.
    Wainwright CE
    Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation.
    Yousef S; Solomon GM; Brody A; Rowe SM; Colin AA
    Chest; 2015 Mar; 147(3):e79-e82. PubMed ID: 25732475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corrector combination therapies for F508del-CFTR.
    Hanrahan JW; Matthes E; Carlile G; Thomas DY
    Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.
    Yu YC; Sohma Y; Hwang TC
    J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanding access to CFTR modulators for rare mutations: The utility of n-of-1 trials.
    Magaret AS; Mayer-Hamblett N; VanDevanter D
    J Cyst Fibros; 2020 Jan; 19(1):1-2. PubMed ID: 31831338
    [No Abstract]   [Full Text] [Related]  

  • 36. [FUTURE THERAPIES FOR CYSTIC FIBROSIS].
    Fajac I
    Rev Prat; 2015 Oct; 65(8):1106-8. PubMed ID: 26749719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effect of CFTR modulator therapy on airway nitric oxide.
    Grasemann H; Klingel M; Avolio J; Prentice C; Gonska T; Tullis E; Ratjen F
    Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31601715
    [No Abstract]   [Full Text] [Related]  

  • 38. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
    Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
    PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
    Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
    J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the basic defect in cystic fibrosis.
    Welsh MJ
    N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.